Cargando…
Protein tyrosine phosphatase receptor type Z1 inhibits the cisplatin resistance of ovarian cancer by regulating PI3K/AKT/mTOR signal pathway
Most patients with ovarian cancer (OC) get remission after undergoing cytoreductive surgery and platinum-based standard chemotherapy, but more than 50% of patients with advanced OC relapse within the first 5 years after treatment and develop resistance to standard chemotherapy. The production of med...
Autores principales: | Wang, Peng, Hu, Yuanjing, Qu, Pengpeng, Zhao, Ying, Liu, Jing, Zhao, Jianguo, Kong, Beihua |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8805848/ https://www.ncbi.nlm.nih.gov/pubmed/35001804 http://dx.doi.org/10.1080/21655979.2021.2022268 |
Ejemplares similares
-
TTK inhibition increases cisplatin sensitivity in high-grade serous ovarian carcinoma through the mTOR/autophagy pathway
por: Qi, Gonghua, et al.
Publicado: (2021) -
Esomeprazole Alleviates Cisplatin Resistance by Inhibiting the AKT/mTOR Pathway in Ovarian Cancer Cells
por: Duan, Jingya, et al.
Publicado: (2023) -
The PI3K/Akt/mTOR pathway in ovarian cancer: therapeutic opportunities and challenges
por: Cheaib, Bianca, et al.
Publicado: (2015) -
LAIR-1 suppresses cell growth of ovarian cancer cell via the PI3K-AKT-mTOR pathway
por: Liu, Yan, et al.
Publicado: (2020) -
Proteomic Analysis of Human Endometrial Tissues Reveals the Roles of PI3K/AKT/mTOR Pathway and Tumor Angiogenesis Molecules in the Pathogenesis of Endometrial Cancer
por: Liu, Zhen, et al.
Publicado: (2020)